“Dapagliflozin and Urinary Tract Infection Risk in Type 2 Diabetes: A Comprehensive Critical Review of Mechanistic, Randomized, and Real-World Evidence”, Trop. j. pharm. life sci., vol. 13, no. 5, pp. 53–68, Oct. 2026, doi: 10.61280/9h681f91.